HeartBeam submits FDA pre-sub for heart attack detection as it races to conserve cash
A pivotal regulatory moment
HeartBeam’s Q2 2026 update carries a clear strategic signal: the company is pushing hard to expand its 12-lead ECG platform into the highest-value indication—heart attack detection. The most concrete evidence is the FDA pre-submission, which management confirmed was filed the same day as the call. As Executive Chairman Richard Ferrari put it, “I am happy to tell you that we actually did submit the pre-sub today.” — Richard Ferrari, CEO · 2026-08-13 That filing initiates a 75-day FDA response window and could pave the way for a pivotal trial before year-end. The pre-sub follows a wave of clinical momentum: the ALIGN-ACS pilot enrolled 134 emergency-room chest-pain patients in under four months, and results were accepted for a full presentation at TCT. The company also highlighted that the HEADSTART-ACS study in Indonesia—a legally sponsored 500-patient trial—has already passed 50% enrollment. These are not just regulatory chores; they build the heart attack detection program that management calls “the tip of the spear.”
Commercial green shoots
On the commercial front, HeartBeam is beginning to convert its concierge-practice strategy into actual revenue streams. Ferrari noted, “the first half of the year, we've referenced the fact that this was our learning stage and that the second half of the year, we would be beginning to gain momentum in generating revenue.” — Richard Ferrari, CEO · 2026-08-13 Early orders have shipped, and initial patients are being onboarded across the four targeted U.S. geographies—New York, Dallas, South Florida, and Southern California. The company is also embedding itself into the new-patient intake workflow at these practices, which should accelerate adoption. The concierge practice market alone represents roughly 1.9 million patients, with an estimated 20% being cardiac-oriented. This is the near-term addressable pool that could drive meaningful subscription revenue, but the company remains guarded about granular metrics, deferring to Q3 for updates.
The balance sheet tightrope
Financially, HeartBeam is walking a narrow line. CFO Tim Cruickshank guided that Q4 2026 operating cash burn would step down to “below $2.5 million per quarter,” — Tim Cruickshank, CFO · 2026-08-13 down from $3.3 million in Q2. However, the company ended Q2 with just $8.8 million in cash and equivalents. The latest 10-Q filing shows a cash runway of only 0.6 quarters—a stark reminder that the company must execute flawlessly on both the clinical and commercial fronts to avoid a dilutive raise. Managements’ baseline spend assumption could increase if the pivotal study starts before year-end, but that would be a “great problem to have,” in the CFO’s words. The company is also trimming costs by pausing tangential projects and paying executives in stock, which helped reduce operating cash outflow by $1 million in Q2.
The strategic pivot is real, and the market has yet to price it in—the stock is down 57% over the past 90 days and sits ~92% below its 2022 peak. If HeartBeam can secure FDA clearance for heart attack detection and demonstrate traction in concierge practices, the optionality is substantial. As Ferrari closed the call,
We will be the first to have sort of pioneered that approach with a handheld device or a wearable, i.e., patch device that can in fact detect a heart attack.
Prior quarters had laid the groundwork: in March, CEO Rob Eno described the ALIGN-ACS pilot as “on the order of about 100 patients” — Robert P. Eno, Chief Executive Officer · 2026-03-12, and in May, Chief Commercial Officer Bryan Humbarger stressed that the first half of the year was “signing and getting these anchor accounts on board.” — Bryan Humbarger, Chief Commercial Officer · 2026-05-14 The current call confirms those seed efforts are now translating to execution, but the clock is ticking on both cash and investor patience.